Vivos Inc. Directors Stack Shares and Secure RSUs, Signaling Executive Confidence in Undervalued Growth

Insider Activity Signals a Strategic Shift at Vivos Inc.

Recent Executive Purchases and a New RSU Deal

On September 15, 2025, President Brad Allan completed a director‑dealing transaction that, while not disclosed in a trade form, reflects a broader pattern of insider confidence. The filing shows an accumulation of 939,235 shares, a sizable block for a private‑market firm, and a subsequent grant of restricted stock units (RSUs) that will vest contingent on future performance. The absence of a price in the filing indicates the RSUs were issued rather than purchased, underscoring management’s long‑term commitment to aligning equity with company performance.

Simultaneously, CEO and President Michael Korenko has been actively buying shares at progressively lower prices—$0.08 in August, $0.07 in early December, and $0.06 at the end of the year—adding roughly 300,000 shares each time. These purchases have pushed his total holdings to over 10.9 million shares, a 60‑plus‑percent increase in his equity stake in just a few months. The trend suggests a belief that the stock is undervalued relative to its 2025 year‑end 52‑week high of $0.1657.

Implications for Investors

The dual narrative of share accumulation and RSU grants carries a clear signal: senior leadership believes the company’s fundamentals are improving, and they are willing to risk significant capital to back that view. For investors, this can be a positive cue, especially given Vivos’ current market cap of roughly $34 million and a price‑to‑earnings ratio that is negative—indicating the firm is still in a growth phase and not yet profitable. The insider activity may reduce the likelihood of a large, coordinated sell‑off, as the owners have a vested interest in maintaining or increasing the stock’s value.

However, the stock’s recent performance—down 22.47 % over the past month and nearly 50 % year‑to‑date—remains a warning sign. The market’s heavy emphasis on social media buzz (over 168 % intensity) and a surprisingly positive sentiment score (+57) could be reflecting speculation rather than fundamentals. Investors should therefore treat the insider purchases as a hopeful indicator rather than a guarantee of imminent upside.

Strategic Outlook for Vivos Inc.

The timing of the RSU grant is also noteworthy. Restricted units that “do not expire” provide a powerful incentive for the president to focus on long‑term value creation. Should Vivos achieve the performance metrics tied to these RSUs—whether revenue targets, operational milestones, or market expansion goals—Allan’s equity will increase substantially, potentially aligning executive and shareholder interests more closely.

On the operational side, Vivos trades OTC rather than on a major exchange, which limits liquidity and can magnify price swings. The recent insider buys could therefore help stabilize the price by increasing the overall share base held by insiders, reducing the probability of a large block sale that might trigger a sharp decline.

Investor Takeaway

For those considering adding Vivos to a portfolio, the insider buying activity and new RSU allocation are encouraging signs that the company’s leadership is confident in its trajectory. Nevertheless, the stock’s volatile recent performance, negative P/E, and OTC listing suggest caution. A prudent strategy would involve monitoring the company’s quarterly earnings reports and any updates on the RSU vesting criteria, while maintaining a diversified position to mitigate the inherent liquidity risks of the OTC market.